万赛维是什么时候上市的？

Valganciclovir in Valganciclovir Hydrochloride Tablets () is the L-valyl ester (prodrug) of ganciclovir. After oral administration, it is rapidly converted into ganciclovir by esterases in the small intestine and liver. It is a synthetic analog of 2'-deoxyguanylic acid, which can inhibit virus replication and prevent CMV virus infection after kidney transplantation.

In May 2001, the U.S. FDA approved the marketing of valganciclovir hydrochloride tablets (Vancevi) for clinical use in the treatment of acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valganciclovir hydrochloride is used to prevent and treat secondary CMV infection in organ transplant recipients. In 2006, Vansavi was launched in my country.

On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Vancevir for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

The recommended induction dose of Vancevir for the treatment of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

In clinical trials, among patients who received Vancevir tablets or intravenous ganciclovir induction therapy followed by Vancevir tablets for maintenance treatment, the average time (median time) from randomization to CMV retinitis exacerbation was: 226 (160) days and 219 (125) days.

Common adverse reactions during use are: diarrhea, low white blood cell, red blood cell and platelet cell counts in blood tests, fever, fatigue, nausea, headache, insomnia, urinary tract infection, shaking movements (tremors), vomiting, etc. These symptoms tend to gradually lessen as the medication is stopped.